Weekly paclitaxel in women age 65 and above with metastatic breast cancer.
We evaluated therapy with weekly paclitaxel 80 mg/m2 in metastatic breast cancer patients age > or =65. There was a low incidence of serious toxicities, with similar tolerability profiles in younger and older patients. Response rates and overall survival times were comparable in the two age groups (<65 and > or =65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer.
Perez
Edith A
EA
Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA. perez.edith@mayo.edu
Vogel
Charles L
CL
Irwin
David H
DH
Kirshner
Jeffrey J
JJ
Patel
Ravi
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002955:Leucovorin